UPS Healthcare Provides Urgent Support For Dr Reddy's Labs Temperature-Sensitive Medicines
Atlanta: UPS has announced a collaboration with Dr Reddy's Laboratories to get 30 tons of pharmaceuticals from India to the United States via Europe. The sensitive cargo had to be shipped within a controlled temperature range to ensure product stability. Given the supply chain challenges and restrictions due to the Coronavirus pandemic, UPS Healthcare and Dr Reddy's created an emergency supply chain plan to replenish pharmaceutical stocks in U.S. markets.
"During this pandemic, moving critical controlled room temperature medicines requires extra planning given the air market capacity demand levels," said Wes Wheeler, president of UPS Healthcare. "We are providing compliant storage, transit and customs clearance expertise to help ensure products move quickly and retain their efficacy. This collaboration enabled Dr Reddy's to replenish its stocks in U.S. locations and provide essential medicines to meet demand."
The time-critical flight originated in Hyderabad, India, moved through UPS's European air hub in Cologne, Germany, and continued to the UPS Worldport® air hub in Louisville, Kentucky.
"UPS works closely with international customs and authorities and will continue to deliver essential medicines and goods to help support the battle against the global Coronavirus pandemic", Release stated
"Dr Reddy's Laboratories aims to ensure that essential medicines are within reach of patients by maintaining an uninterrupted supply globally. Our commitment to ensuring accelerated access to affordable and innovative medicines to millions of patients around the world, holds significantly more than ever in the present times," said Puvvala Yugandhar, head of global supply chain, Dr Reddy's Laboratories. "In this critical situation of the disruption caused by the Coronavirus, we connected with the UPS Healthcare team who helped ensure that critical medicines reach pharmacies and hospitals in the U.S. on time for patients."
Read also: Dr Reddy's Labs launches generic Ocaliva in India
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.